FDA Accepts Axsome's AXS-12 NDA for Narcolepsy Cataplexy, Setting May 2027 PDUFA Date
AXSM has more than doubled off its 52-week low of $96.09.
Summary
The FDA has accepted the NDA for AXS-12 in narcolepsy cataplexy, with a PDUFA date of May 1, 2027. No advisory committee is currently planned, signaling a potentially smooth review.
Key Events · Product Development and Regulatory · AXSM
-
FDA Accepts AXS-12 NDA
The FDA has accepted the New Drug Application for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, a serious orphan neurological condition.
-
PDUFA Date Set for May 1, 2027
A clear regulatory timeline is now in place, with the FDA setting a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.
-
No Advisory Committee Planned
The FDA indicated it does not currently plan to hold an advisory committee meeting, suggesting a straightforward review process and reducing a common source of uncertainty.
-
Pipeline Expansion in CNS
AXS-12 strengthens a growing CNS portfolio that already includes approved treatments for major depressive disorder, Alzheimer's agitation, excessive daytime sleepiness, and migraine.
Analysis · AXSM · Life Sciences
A major pipeline milestone has been reached with the FDA's acceptance of the NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, setting a PDUFA date of May 1, 2027. For a company with a $12.1B market cap, this adds a promising new indication to its CNS portfolio. The review path looks smoother than usual because the FDA currently does not plan an advisory committee meeting, removing a common overhang. Combined with recent strong commercial execution and a settled patent landscape for Sunosi, this regulatory catalyst reinforces the growth narrative.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXSM was trading at $229.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $96.09 to $260.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.